Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2011-08-02
2011-08-02
Lucas, Zachariah (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S184100, C424S185100, C424S189100
Reexamination Certificate
active
07989162
ABSTRACT:
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
REFERENCES:
patent: 4946677 (1990-08-01), Dorner et al.
patent: 5237053 (1993-08-01), Dorner et al.
patent: 6100380 (2000-08-01), Green et al.
patent: 6436391 (2002-08-01), Foster et al.
patent: 6555311 (2003-04-01), Locarnini et al.
patent: 7405039 (2008-07-01), Bartholomeusz et al.
patent: 7422848 (2008-09-01), Bozdayi
patent: 2003/0124096 (2003-07-01), Locarnini et al.
patent: 2004/0005541 (2004-01-01), Bartholomeusz et al.
patent: 2004/0194155 (2004-09-01), Delaney et al.
patent: 2006/0051743 (2006-03-01), Bartholomeusz et al.
patent: 734831 (2001-06-01), None
patent: 2 309 379 (2001-12-01), None
patent: 02 52 064 (1987-06-01), None
patent: 07 17 106 (1995-11-01), None
patent: WO 90/06696 (1990-06-01), None
patent: WO 93/24636 (1993-12-01), None
patent: WO 97/41234 (1997-11-01), None
patent: WO 98 21317 (1998-05-01), None
patent: WO 00/61758 (2000-10-01), None
patent: WO 01 57244 (2001-08-01), None
patent: WO 01 94559 (2001-12-01), None
patent: WO 03/066841 (2003-08-01), None
patent: WO 2004/031224 (2004-04-01), None
Bartholomeusz et al., U.S. Appl. No. 12/303,942, filed Dec. 8, 2008.
Angus et al. “Resistance to oadefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase” 2003,Gastro., 125(2):292-7.
Barbhaiya et al. “Iron uptake and detection of an outer membrane iron-siderophore receptor protein fromPseudomanas aeruginosaPA01” 1998,FEMS Microbiol. Lett., 51:169-72.
Bartenschlager et al. “Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome” 1992,EMBO. J., 7:4185-92.
Bartholomeusz et al. “Mutations in the hepatitis B virus polymerase gene that are associated with resistance to famciclovir and lamivudine” 1997,Int. Anti. News, 5(8):123-4.
Bartholomeusz et al. “Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease” 1998,Viral Hepatitis Rev., 4:167-87.
Benhamou et al. “Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study” 2001,Lancet, 358:718-23.
Benzaria et al. “Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability” 1996,J. Med. Chem., 39:4958-65.
Bowie et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” 1990,Science, 247(4948):1306-10.
Brown et al. “Cloning and characterization of the katB gene ofPseudomonas aeruginosaencoding a hydrogen peroxide-inducible catalase: purification of KatB, cellular localization, and demonstration that it is essential for optimal resistance to hydrogen peroxide” 1995,J. Bacteriol., 177:6536-44.
Burgess et al. “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue” 1990,J. Cell Biol., 111:2129-38.
Calio et al. “Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates” 1994,Antiviral Res., 23:77-89.
Chang et al. “Mechanism of translation of the Hepadnaviral polymerase (P) gene” 1990,Proc. Natl. Acad. Sci. USA, 87:5158-62.
Coates et al. “(-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro” 1992,Antimicrob. Agents Chemother., 36:733-9.
Database EMBL [Online] EBI; Hepatitis B virus mutante polymerase gene, Jun. 28, 2000, Yeh C.-T.: XP002510516, retrived from EBI Database accession No. AF156492.
Database EMBL [Online] EBI; Woodchuck hepatitis virus, Sep. 20, 2001, Yamamoto, T: XP002510517, retrived from EBI Database accession No. AF410856.
Database UniProt [Online], Jul. 1, 1993; “Protein P [Includes: DNA-directed DNA polymerase (EC<A HREF=“http://srs.ebi.ac.uk/srsbin/cgi-bin/wgetz?[enzyme-ECNumber:2.7.7.49]+-e”>2.7.7</A); RNA-directed DNA polymerase (EC < A HREF=“http://srs.ebi.ac.uk/srsbin/cig-bin/wgetz?[enzyme-ECNumber:2.7.7.49]+-e”>2.7.7.49</A>); Ribonuclease H (EC <A”.
Dienstag et al. “Lamivudine as initial treatment for chronic Hepatitis B in the United States” 1999,N. Engl. J. Med., 341:1256-63.
Doong et al. “Inhibition of the replication of Hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues” 1991,Proc. Natl. Acad. Sci. USA, 88:8495-9.
Estacio et al. “Nucleotide sequence of a hepatitis B virus genome of subtype adw isolated from a Philippino: Comparison with the reported three genomes of the same subtype” 1988,J. Gast. Hepat., 3:215-22.
Fernandes et al. “Antibodies to cell envelope proteins ofPseudomonas aeruginosain cystic fibrosis patients” 1981,Infect. Immun., 33:527-32.
Fiser et al. “Modeling of loops in protein structures” 2000,Protein Sci., 9:1753-73.
Frick et al. “Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus” 1993,Antimicrob. Agents Chemother., 37: 2285-92.
Gardsvoll et al. “Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis” 1999,J. Biol. Chem., 274(53):37995-8003.
Georgiadis et al. “Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase” 1995,Structure, 3:879.
Gilson et al. “A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection” 1999,J. Viral Hepat., 6:387-95.
Greenberg “Bacterial genomics: pump up the versatility” 2000,Nature, 406:947-8.
Heathcote et al. “Loss of serum HBV DNA and HBeAg and seroconversion following shoert term (12 weeks) Adefovir Dipivoxil therapy in in chronic hepatitis B: two two placebo-controlled phase II studies” 1998,Hepatol., 28:A620.
Hess et al. “Inhibition of hepatits B virus specific DNA polymerase by intercalating agents” 1980,Med. Microbiol. Immunol., 168:25-34.
Hoyer-Hansen et al. “The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction” 1997,FEBS Lett., 420(1):79-85.
Jarvis et al. “A review of its therapeutic potential in chronic Hepatitis B” 1999,Drugs58:101-41.
Khan et al. “The functional analysis of directed amino-acid alterations in ZntR fromEscherichia coli” 2002,Biochem. Biophys. Res. Commun., 299(3):438-45.
Kukor et al. “Cloning and expression of the catA and catBC g
Angus Peter William
Ayres Anna
Bartholomeusz Angeline Ingrid
Locarnini Stephen Alister
Sievert William
Austin Health
Baker & Botts L.L.P.
Blumel Benjamin P
Lucas Zachariah
Melbourne Health
LandOfFree
Viral variants with altered susceptibility to nucleoside... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Viral variants with altered susceptibility to nucleoside..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral variants with altered susceptibility to nucleoside... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729883